S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Exelixis and Swedish Orphan Biovitrum AB (Sobi) Extend and Restructure Distribution Agreement for COMETRIQ® for Medullary Thyroid Cancer (2015/1/7)|
|Exelixis to Release Fourth Quarter and Full Year 2014 Financial Results on Tuesday, February 24, 2015 (2015/2/2)|
|Exelixis Announces Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update (2015/2/24)|
|Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced Melanoma (2014/12/15)|
|Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer (2014/12/1)|
|Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma (2015/2/19)|
|Exelixis to Present at the Leerink Global Healthcare Conference on Wednesday, February 11 (2015/1/29)|
|Exelixis to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3 (2015/2/26)|
|UPDATE: These are the most profitable Nasdaq biotech companies (2015/2/27)|
|These are the most profitable Nasdaq biotech companies (2015/2/27)|
Click above to view more mutual fund data and stats for exel - Exelixis Inc.